RetinAI and RCA join forces for most comprehensive US Real World Evidence database in ophthalmology

Our portfolio company RetinAI, a leader in clinical and imaging data management software and advanced analytics using AI, and Retina Consultants of America (RCA), the largest retina care provider in the U.S. with more than 1.7M annual patient visits and over 200 locations in the U.S., have announced a strategic partnership to develop the most extensive and AI-insight driven Real World Evidence (RWE) U.S.-based database in Ophthalmology.

This groundbreaking partnership will leverage RetinAI‘s innovative digital health technologies and RCA’s robust network of clinics to analyze real-world health clinical and imaging data. The result will be a comprehensive resource that provides valuable insights into health outcomes, medication adherence, and the effectiveness of various treatment protocols. By using RCA’s quality-driven datasets and best-in-practice imaging standards for ophthalmic care and RetinAI’s Discovery® platform to aggregate, organize and analyze multimodal data at scale including the company’s certified and advanced research AI models for biomarker analysis and predictive disease analytics, the database will combine the best in clinical and imaging data with exceptionally detailed insights.

With the growing demand for real-world data from the industry, this partnership is poised to make a significant impact on data-driven decisions. The RWE database will offer healthcare stakeholders an unparalleled opportunity to gain insights into drug efficacy, improve drug development processes, and enhance patient care.

“Through this partnership with RCA, we are revolutionizing the efficiency and robustness of making decisions around patient care, with an unprecedented scale of biomarker-driven insights from quality-driven, real world data. This will enable an elevated level of target-based research and patient-centric care for continuous improvement to patient outcomes and the introduction of new precision-based medicines.” states Dr. Carlos Ciller, CEO of RetinAI 

For more details, please refer to the official press release on the company’s website.